Abstract
The IL-17 family in humans consists of six distinct cytokines (IL-17A-F) that can interact with five IL-17 receptors (IL-17RA-E). The interaction between these cytokines and their receptors are critical in mediating host defenses while also making major contributions to inflammatory and autoimmune responses as demonstrated through both in vitro and in vivo experiments as well as human clinical trials. Inhibition of the IL-17A/IL-17RA interaction by monoclonal antibodies has also displayed remarkable efficacies in clinical trials against psoriasis and other autoimmune diseases. Recently, we and others reported the identification and characterization of both small-molecule and peptide IL-17A antagonists. These non-antibody IL-17A antagonists can effectively and selectively disrupt the IL-17A/IL-17RA complex and may provide alternative modalities to treat IL-17-related autoimmune and inflammatory diseases. This chapter summarizes the reported crystal structures of the IL-17 cytokines, their complexes with IL-17RA, and their complexes with both monoclonal antibodies as well as small-molecule and peptide antagonists.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567
Wright JF et al (2008) The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 181:2799–2805
Chang SH, Dong C (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17:435–440
Liang SC et al (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179:7791–7799
Rickel EA et al (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181:4299–4310
Hymowitz SG et al (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 20:5332–5341
Song X et al (2011) IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 12:1151
Toy D et al (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177:36–39
Hu Y et al (2010) IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 184:4307–4316
Novatchkova M, Leibbrandt A, Werzowa J, Neubuser A, Eisenhaber F (2003) The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 28:226–229
Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10:479–489
Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129:311–321
Chang SH, Park H, Dong C (2006) Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 281:35603–35607
Qian Y et al (2007) The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 8:247
Hwang SY et al (2004) IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 6:R120–R128
Mills KH (2008) Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38:2636–2649
van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5:549–553
Wright JF et al (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4 + T cells. J Biol Chem 282:13447–13455
Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226:87–102
Ely LK, Fischer S, Garcia KC (2009) Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 10:1245–1251
Ramirez-Carrozzi V et al (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12:1159–1166
Infante-Duarte C, Horton HF, Byrne MC, Kamradt T (2000) Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 165:6107–6115
Shi Y et al (2000) A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 275:19167–76
Lee J et al (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276:1660–1664
Kullak-Ublick GE, Stieger B, Hagenbuch B, Meier P (2000) Hepatic transport of bile salts. Semin Liver Dis 20:273–292
Chang SH et al (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35:611–621
Puel A et al (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207:291–297
Puel A et al (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65–68
Yilmaz S, Cicek N, Coskun M, Yegin O, Alpsoy E (2012) Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 304:465–469
Ziolkowska M et al (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164:2832–2838
Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM (2008) TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 10:R93
Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454–467
Griffiths CEM et al (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet
Langley RG et al (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338
Hueber W et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72
Papp K et al (2014) Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 71:1183–1190.e3
Administration, U.S.F.a.D (2015) FDA approves new psoriasis drug Cosentyx. U.S. FDA press release. U.S. Food and Drug Administration
Administration, U.S.F.a.D. (2016) FDA approves new psoriasis drug Taltz. FDA press release
Kotake S et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352
Chabaud M et al (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970
Lubberts E et al (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167:1004–1013
Lubberts E et al (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659
Amgen (2015) Amgen to terminate participation in co-development and commercialization of brodalumab. In: Amgen News Release, vol 2015. Amgen
Arkin MR, Tang Y, Wells JA (2014) Small-molecule inhibitors of protein-protein interactions: progressing toward the Reality. Chem Biol 21:1102–1114
Liu S et al (2016) Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide. Sci Rep 6:26071
Ting JP et al (2018) Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery. PLoS ONE 13:e0190850
Alexander SL et al (2014) Compounds for modulating IL-17, vol WO2014066726A2. Ensemble Therapeutics Corporation, USA
Taylor M et al (2015) Macrocyclic compounds for modulating IL-17, vol PCT/US2015/0005319. U.S. Patent and Trademark Office, USA
Liu S et al (2013) Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 4:1888
Goepfert A, Lehmann S, Wirth E, Rondeau J-M (2017) The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Sci Rep 7:8906
Zhang B et al (2014) Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved [alpha]-helix for Act1 binding and IL-17 signaling. Acta Crystallogr Sect D 70:1476–1483
Gerhardt S et al (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 394:905–921
Liu S et al (2016) Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. Sci Rep 6:30859
Ho AW et al (2010) IL-17RC is required for immune signaling via an extended SEFIR domain in the cytoplasmic tail. J Immunol (Baltimore, Md.: 1950) 185:1063–1070
Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA (2006) Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA 103:2788–2793
Wang X, Rickert M, Garcia KC (2005) Structure of the quaternary complex of interleukin-2 with Its α, ß, and γc receptors. Science 310:1159–1163
Verstraete K et al (2014) Structural basis of the proinflammatory signaling complex mediated by TSLP. Nat Struct Molecular Biol 21:375
Guettner A, Machacek M, Papavassilis C, Sander O (2012) Methods of treating psoriasis using il-17 antagonists. Novartis Ag
Liu L et al (2016) Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 9:39–50
Allan B, Chow CK, Liu L, Lu J, Tetreault JW (2011) Anti-il-17 antibodies, vol US20110027290 A1. Google Patents
Spindeldreher S et al (2018) Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Therapy 8:57–68
Chiricozzi A et al (2011) Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131:677–687
Zhong X et al (2013) Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions. J Biol Chem 288:1409–1419
Vugmeyster Y, Zhang Y, Zhong X, Wright J, Leung SS (2014) Pharmacokinetics of anti-IL17A and anti-IL22 peptide–antibody bispecific genetic fusions in mice. Int Immunopharmacol 18:225–227
DeLano W (2002) The PyMOL molecular graphics system. The PyMOL molecular graphics system, Version 1.2r3pre, Schrödinger, LLC
Acknowledgements
The author thanks his Pfizer coworkers and former coworkers who worked on IL-17A antagonist project, and Ruth Sommese for comments on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Liu, S. (2019). Structural Insights into the Interleukin-17 Family Cytokines and Their Receptors. In: Jin, T., Yin, Q. (eds) Structural Immunology. Advances in Experimental Medicine and Biology, vol 1172. Springer, Singapore. https://doi.org/10.1007/978-981-13-9367-9_5
Download citation
DOI: https://doi.org/10.1007/978-981-13-9367-9_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9366-2
Online ISBN: 978-981-13-9367-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)